Intangible Assets

TENX does not show evidence of durable brand, proprietary IP, or regulatory exclusivity in the provided filings-based inputs, so it lacks a clear source of peer-resistant pricing power.

The absence of positive ROIC and the reported TTM ROIC of -60.4% indicate that any intangible advantage is not translating into economic returns versus peers.

No disclosed long-run margin or growth history is provided, which limits support for persistent customer preference or differentiated clinical adoption relative to peers.

Compared with stronger medtech peers that can point to protected products, installed clinical workflows, or recognized brands, TENX appears materially less protected on intangible assets.

Switching Costs

The available data do not indicate embedded software, consumables lock-in, or workflow integration that would make customers costly to replace TENX versus peers.

A negative TTM ROIC suggests customers are not locked in by a monetizable switching structure that preserves margins or retention.

No evidence is provided of multi-year contracts, regulatory dependency, or platform integration that would raise switching costs above commodity levels.

Relative to peers with installed-base service revenue or recurring consumables, TENX appears to have limited customer lock-in.

Network Effects

TENX does not appear to operate a platform, marketplace, or data network where more users directly increase value for other users.

The provided metrics show no sign of scale-driven monetization, and the negative ROIC argues against a self-reinforcing adoption loop.

No filings-based evidence is provided of ecosystem participation, developer dependence, or data accumulation that would compound over time.

Compared with peer businesses that benefit from physician, hospital, or patient network effects, TENX shows no visible network moat.

Cost Advantage

The TTM ROIC of -60.4% is inconsistent with a structural cost advantage, because a lower-cost position should عادة support positive excess returns over peers.

No gross margin or operating margin history is provided to show that TENX converts scale into superior unit economics.

The available efficiency metrics do not show asset productivity advantages, with asset turnover reported at 0 and cash conversion cycle at 0, which does not evidence a durable cost edge.

Relative to peers with manufacturing scale, procurement leverage, or high fixed-cost absorption, TENX does not demonstrate a defensible cost advantage.

Efficient Scale

TENX does not show evidence of serving a niche market where one or two players can profitably dominate and deter entry.

The negative ROIC suggests the company is not currently capturing the economics that would typically accompany efficient scale in a constrained market.

No filings-based evidence is provided of regulatory barriers, specialized distribution, or capacity constraints that would limit peer entry and support durable pricing power.

Compared with peers in narrow medical-device niches, TENX appears to lack the scale-based market structure needed for efficient-scale protection.

Overall Score

TENX appears to have a weak and non-durable moat versus peers because the provided evidence shows deeply negative capital returns and no clear filings-based support for intangible assets, switching costs, network effects, cost advantage, or efficient scale.